CN104740138A - Composition containing aloe, probiotics and prebiotics and application of composition - Google Patents

Abstract

The invention discloses a composition and an application thereof in regulating intestinal flora of animals. The composition contains aloe, probiotics and prebiotics, wherein the mass ratio of the aloe to the probiotics to the prebiotics is (6 to 3 to 1)-(6 to 1 to 3). The inventor discovers that the composition disclosed by the invention can effectively promote the proliferation of useful bacteria such as bifidobacterium and lactobacilli in animal intestines, so as to effectively regulate the intestinal flora of animals; therefore, the composition can be used for preventing or treating diabetes on the basis of the effect of the intestinal flora.

Description

Compositions comprising aloe vera, probiotics and prebiotics and uses thereof

technical field

The present invention relates to a composition and its use, in particular to an aloe composition and its use in preparing medicine and food, medicine and food. the

Background technique

According to research reports, 90% of human cells are not human cells, but microorganisms. Humans and their symbiotic microorganisms together form a "super organism". Therefore, it can be said that the human body has two sets of genomes, one is its own and the other is that of microorganisms. The composition, structure and proportion of intestinal flora are closely related to human health and disease occurrence. Different gut flora profiles can cause or prevent disease; can cause obesity or cause emaciation; can induce diabetes or prevent diabetes. Different flora profiles produce different physiological and pathological effects. They are not only the inducing or initiating factors of health and disease; they are also the "barometer" of health and disease. At present, studies have confirmed that various human diseases such as diabetes, hypertension, hyperlipidemia, and cancer are closely related to intestinal flora. the

However, the current research on regulating the intestinal flora of animals still needs to be in-depth. the

Contents of the invention

The present invention aims to solve at least one of the technical problems existing in the prior art. Therefore, an object of the present invention is to propose a means for effectively regulating the intestinal flora of animals. the

Thus, in one aspect of the invention, the invention provides a composition. According to an embodiment of the present invention, the composition comprises aloe, probiotics and prebiotics, wherein the mass ratio of the aloe, probiotics and prebiotics is 6:3:1˜6:1:3. According to some embodiments of the present invention, the composition of the present invention can effectively promote the proliferation of beneficial flora such as Bifidobacterium, Lactobacillus, and Lactococcus in the intestinal tract of animals, that is, it can effectively regulate the intestinal flora of animals, and then based on The role of intestinal flora plays a role in the prevention or treatment of diabetes. the

It should be noted that the species of animals referred to by the term "animal" in the expression "modulating the intestinal flora of an animal" used herein is not particularly limited. According to an embodiment of the present invention, the animal can be any animal with intestinal organs, preferably a mammal, more preferably a rat, a mouse, a human, and most preferably a human. In addition, the expression "prevention or treatment" used herein mainly refers to the prevention or auxiliary treatment of diabetes. the

According to the embodiment of the present invention, the source of the aloe, that is, the form of supply is not particularly limited, for example, it can be obtained directly from the market, or it can be provided in various aloe products. According to some embodiments of the present invention, the aloe is provided in at least one form selected from aloe powder, aloe juice, aloe gel, and aloe extract. the

According to the embodiments of the present invention, the types of probiotics are not particularly limited, as long as they can effectively regulate the intestinal flora of animals, those skilled in the art can flexibly choose according to the actual situation. According to some embodiments of the present invention, the probiotics are common probiotics in the human body, such as but not limited to Faecalibacterium, Eubacterium, Clostridium, Fusobacterium, Roseborella, and Faecococcus , Bifidobacterium, Butyvibrio, Lactobacillus or Lactococcus. According to some specific examples of the present invention, the probiotics are selected from the group consisting of Eubacterium rectum, Barretella gluconovorans, Barretella enterica, Faecalibacterium prauszii, Clostridium butyricum, Bacillus coagulans, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium adolescentis, Lactobacillus delbrueckii bulgaricus, Lactobacillus acidophilus, Streptococcus thermophilus, Lactobacillus casei subsp. Lactobacillus reuteri, Bifidobacterium lactis, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus delbrueckii subsp, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus johnsonii, Lactobacillus plantarum, murine Lactobacillus salivarius, Lactobacillus salivarius, Propionibacterium frescheri subsp. Shermanii, Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. diacetyl, Leuconostoc enterococci subsp. at least one of . the

According to the embodiments of the present invention, the type of the prebiotic is not particularly limited, as long as it can effectively promote the growth of beneficial bacteria. According to some embodiments of the present invention, the prebiotic is at least one selected from inulin, propolis, chitooligosaccharides, fructooligosaccharides, galactooligosaccharides, and xylooligosaccharides. Thereby, the growth of beneficial bacteria can be effectively stimulated. the

In the second aspect of the present invention, the present invention provides the use of the aforementioned composition in regulating intestinal flora of animals. The inventors have surprisingly found that the composition of the present invention can significantly increase the number of beneficial bacteria in the intestinal tract of the animal, regulate the intestinal flora of the animal, and then effectively reduce the blood sugar concentration of the animal based on the effect of the intestinal flora, Thereby effectively preventing or treating diabetes. the

According to the embodiments of the present invention, taking the composition of the present invention does not have any toxic side effects, so the dosage of the composition is not particularly limited, and those skilled in the art can flexibly choose according to the health status of the subject to be administered. According to some embodiments of the present invention, the composition is administered to the animals at a dose of 0.5 g aloe/kg/d. Thus, the number of beneficial bacteria in the intestinal tract of the administered animal is significantly increased, that is, the effect of the composition of the present invention on regulating the intestinal flora of the animal is remarkable. the

It should be noted that the term "administration" used herein should be understood in a broad sense. In addition to conventional drug administration, it can be understood as feeding or providing the food for the composition or food. the

In the third aspect of the present invention, the present invention provides the use of the aforementioned composition in the preparation of medicaments. According to an embodiment of the present invention, the medicament is used for regulating intestinal flora of animals. the

The above-mentioned drugs can be used to regulate the intestinal flora of animals, and then exert the effect of lowering blood sugar through the action of the intestinal flora. Thus, according to some embodiments of the present invention, the medicament is used for preventing or treating diabetes. the

According to the embodiments of the present invention, the dosage of the drug is not particularly limited, as long as it can effectively regulate the animal intestinal flora. According to some specific examples of the present invention, the drug is administered to the animal at a dose of 0.5 g aloe/kg/d. As a result, the number of beneficial bacteria in the intestinal tract of the administered animals was significantly increased, and the blood sugar concentration was significantly reduced. the

In the fourth aspect of the present invention, the present invention also provides a medicine. According to an embodiment of the present invention, the medicine comprises: the aforementioned composition; and a pharmaceutically acceptable excipient. The inventors have surprisingly found that the drug of the present invention can significantly increase the number of probiotics such as Bifidobacteria, Lactococcus, and Lactobacillus in the intestinal tract of the administered animal, regulate the intestinal flora of the animal, and then through the effect of the intestinal flora Effectively prevent or treat diabetes. the

According to the embodiments of the present invention, the types of excipients are not particularly limited, as long as the drug can be formed into a dosage form that is easy to administer. According to some specific examples of the present invention, the excipient is at least one selected from binders, fillers, coating polymers, plasticizers, glidants, disintegrants and lubricants. the

According to the embodiments of the present invention, the dosage form of the medicament of the present invention is not particularly limited, as long as it can be administered conveniently. According to some specific examples of the present invention, the drug is in the form of at least one selected from capsules, pills, tablets, granules, oral liquids, internal ointments, aerosols and sprays. According to some preferred embodiments of the present invention, the medicament is in the form of capsules. Thus, administration is facilitated. the

According to an embodiment of the present invention, the medicament is used for regulating intestinal flora of animals. Furthermore, the effect of lowering blood sugar can be exerted through the action of intestinal flora. Therefore, according to other embodiments of the present invention, the medicament is used for preventing or treating diabetes. the

According to the embodiments of the present invention, the dosage of the drug of the present invention is not particularly limited, and in practical applications, it can be flexibly selected according to the health status of the subject to be administered. According to some embodiments of the present invention, the dosage of the drug is 0.5g aloe/kg/d. As a result, the number of probiotics such as Bifidobacterium, Lactobacillus, and Lactococcus in the intestines of the animals being administered significantly increased, and the effect of regulating the intestinal flora of the animals was remarkable. Furthermore, based on the effect of the intestinal flora, it could effectively reduce the Blood sugar concentration of drug animals, thereby preventing or treating diabetes. the

In the fifth aspect of the present invention, the present invention also provides a food. According to an embodiment of the present invention, the food comprises the aforementioned composition; and food acceptable additives. The inventors found that the food of the present invention can significantly increase the number of probiotics such as Bifidobacterium and Ruminococcus in the intestinal tract of the animal being administered, effectively regulate the intestinal flora of the animal, and then effectively prevent or treat diabetes. the

It should be noted that the term "food" used herein should be understood in a broad sense, and it can be in any edible form, that is, in addition to conventional food forms, the food of the present invention can also be health care products, drinks, etc. . the

In the sixth aspect of the present invention, the present invention also provides the use of the aforementioned medicine or food in regulating the intestinal flora of animals. According to the embodiments of the present invention, administering the above-mentioned medicine or food of the present invention to animals can significantly increase the number of probiotics such as Bifidobacterium, Lactococcus, and Lactobacillus in the intestinal tract of the animal being administered, and effectively regulate the animal's health. Intestinal flora, and then effectively prevent or treat diabetes through the role of intestinal flora. the

According to the seventh aspect of the present invention, the present invention also provides a method for regulating intestinal flora of animals. According to an embodiment of the present invention, the method is to administer the aforementioned composition, drug or food of the present invention to the animal. According to the embodiments of the present invention, using the method of the present invention can significantly increase the number of probiotics such as Bifidobacterium, Lactococcus, and Lactobacillus in the intestinal tract of the administered animal, effectively regulate the intestinal flora of the animal, and then pass the intestinal bacteria The role of the group is effective in preventing or treating diabetes. the

In addition, according to the embodiments of the present invention, the composition and the food or medicine of the present invention containing the composition can regulate the intestinal flora of animals better than the effect of aloe vera, probiotics or prebiotics as a single component. the

It should also be noted that the composition, medicine, food and their use in regulating animal intestinal flora of the present invention were unexpectedly discovered by the inventors of the present invention through hard creative work and a lot of experimental work. the

The present invention has at least one of the following advantages:

1. In the composition of the present invention, all raw materials are taken from nature, are derived from nature, and do not contain any chemical preparations, have no toxic and side effects, are safe and reliable; the sources of raw materials are widely and easily available, the prescription compatibility is scientific and reasonable, the curative effect is definite, and it has synergistic enhancement. efficacy; and the preparation process is simple, safe in storage, transportation and application, low in production cost, and easily accepted by consumers;

2. The composition, medicine and food of the present invention have been proved to have no toxic side effects through animal function tests and human consumption tests, can significantly reduce the fasting blood sugar of patients, have a significant hypoglycemic effect, and meet the requirements and development trends of health care products , suitable for people with high blood sugar, obesity and the elderly, through daily consumption, from the perspective of treating the root cause, by regulating intestinal flora, lowering blood sugar, and finally achieving the purpose of protecting health. the

3. Through the reasonable combination of pure natural raw materials, the present invention realizes convenient and significant health effects such as hypoglycemia, obvious drug effect, good safety, stable quality, long-term preservation of the product, and provides a new way for people's daily health care. s Choice. the

Additional aspects and advantages of the invention will be set forth in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. the

Detailed ways

Embodiments of the present invention are described in detail below. The embodiments described below are exemplary only for explaining the present invention and should not be construed as limiting the present invention. If no specific technique or condition is indicated in the examples, it shall be carried out according to the technique or condition described in the literature in this field or according to the product specification. The reagents or instruments used were not indicated by the manufacturer, and they were all commercially available conventional products. the

Example 1

According to the formula shown in Table 1, the composition was prepared according to the following process. the

Table 1 Composition formula of the present invention (weight unit of raw material: part)

The specific operation steps are as follows:

1. Aloe vera powder

The aloe vera powder that the present invention adopts can be derived from the market, and can also be prepared by itself, and the preparation method is a common method. the

2. Aloe Vera Clostridium Butyricum Propolis Capsules

Clostridium butyricum strains are cultivated in liquid, collected and washed, and dried to prepare active bacterial powder. Mix aloe vera powder, Clostridium butyricum powder and propolis evenly according to the ratio of 6/3/1, and then pack it in No. 0 capsules to obtain aloe Clostridium butyricum propolis capsules, wherein the number of live bacteria of Clostridium butyricum is not less than 1.0×10 ⁸ CFU/g.

3. Aloe Bifidobacteria Inulin Capsules

Bifidobacteria strains are cultured in liquid, collected and washed, dried to prepare active bacteria powder, mix aloe vera powder, bifidobacteria powder and inulin according to the ratio of 3/1/1, and then use No. 0 capsule Packing to obtain bifidobacterium aloe inulin capsules, wherein the number of viable bifidobacteria is not less than 1.0×10 ⁸ CFU/g.

4. Aloe plant Lactobacillus chitosan oligosaccharide capsules

Lactobacillus plantarum strains are cultured in liquid, collected and washed, and dried to prepare active bacterial powder. Stir aloe powder, Lactobacillus plantarum powder and chitosan oligosaccharide evenly according to the ratio of 6/3/1, and then use No. 0 Packing in capsules to obtain Lactobacillus plantarum chitosan oligosaccharide capsules, wherein the viable count of Lactobacillus plantarum is not less than 1.0×10 ⁸ CFU/g.

5. Aloe Vera Intestinal Rosie Bacillus Fructose Oligosaccharide Capsules

Enterobacteriaceae Roseria species are cultivated in liquid, collected and washed, and dried to prepare active bacterial powder. According to the ratio of 6/3/1, aloe vera powder, enterica Roseriabacteria powder and oligomerization Stir the fructose evenly, and then pack it in No. 0 capsules to obtain fructo-oligosaccharide capsules of B. enterica Ros. B. fructooligosaccharides, wherein the number of viable bacteria of B. enterica Ros. B. is not less than 1.0×10 ⁸ CFU/g.

6. Aloe Lactobacillus acidophilus galactooligosaccharide capsules

Lactobacillus acidophilus strains are cultured in liquid, collected and washed, and dried to prepare active bacteria powder. Stir aloe vera powder, Lactobacillus acidophilus powder and galactooligosaccharide evenly according to the ratio of 12/5/3, and then Packaged in No. 0 capsules to obtain Lactobacillus aloe acidophilus galacto-oligosaccharide capsules, wherein the viable count of Lactobacillus acidophilus is not less than 1.0×10 ⁸ CFU/g.

7. Aloe fermented Lactobacillus xylooligosaccharide capsules

The strains of Lactobacillus fermentum are cultured in liquid, collected and washed, and dried to prepare active bacterial powder. Stir the aloe vera powder, Lactobacillus fermentum powder and xylo-oligosaccharide evenly according to the ratio of 12/3/5, and then use 0 packed in capsules to obtain xylooligosaccharide capsules of Lactobacillus fermentum, wherein the number of viable Lactobacillus fermentum is not less than 1.0×10 ⁸ CFU/g.

8. Aloe Bacillus coagulans fructooligosaccharide capsules

Bacillus coagulans strains are cultivated in liquid, collected and washed, and dried to prepare active bacteria powder. Stir aloe powder, Bacillus coagulans powder and fructooligosaccharides evenly according to the ratio of 6/3/1, and then use No. 0 Packing in capsules to obtain Bacillus coagulans fructo-oligosaccharide capsules, wherein the number of viable Bacillus coagulans is not less than 1.0×10 ⁸ CFU/g.

9. Aloe Streptococcus thermophilus inulin capsules

Streptococcus thermophilus strains are cultured in liquid, collected and washed, and dried to prepare active bacteria powder. Stir aloe powder, Streptococcus thermophilus bacteria powder and inulin evenly according to the ratio of 6/3/1, and then use 0 No. capsules are packaged to obtain Aloe Streptococcus thermophilus inulin capsules, wherein the number of viable Streptococcus thermophilus is not less than 1.0×10 ⁸ CFU/g.

10. Aloe Lactobacillus reuteri Chitooligosaccharide Capsules

Lactobacillus reuteri strains are cultured in liquid, collected and washed, and dried to prepare active bacterial powder. Stir aloe vera powder, Lactobacillus reuteri bacterial powder and chitosan oligosaccharide evenly according to the ratio of 6/3/1. Then pack it in No. 0 capsules to obtain Lactobacillus reuteri chitosan oligosaccharide capsules, wherein the number of live bacteria of Lactobacillus reuteri is not less than 1.0×10 ⁸ CFU/g.

11. Aloe Lactobacillus Plantarum Inulin Tablet Candy

Filter the aloe vera powder, Lactobacillus plantarum powder, and inulin through an 80-mesh sieve, the proportion of ingredients is 6:3:1, and the mixing time is 15 minutes. The temperature during drying is 60°C, the moisture content of the granules is 0.5%, and the ambient humidity is controlled during tablet molding, and the relative humidity is 60%. the

Embodiment 2: determination of acute toxicity

Use 6-week-old special pathogen-free (SPF) SD rats to conduct acute toxicity test, the specific operation is as follows:

Each composition prepared in Example 1 was suspended in 0.5% methylcellulose solution, and was orally administered to 5 SD rats in each group at a dose of 1 g/kg, 5 g/kg and 10 g/kg respectively , observe the death, clinical symptoms and body weight changes of the rats, and conduct blood tests and blood biochemical tests. At the time of autopsy, any abnormalities in the gastrointestinal tissues of the chest and abdomen were visually inspected. the

Experimental results: each composition of the present invention did not cause any specific clinical symptoms, body weight change or death, and there was no change in blood test, blood biochemical test and autopsy. Therefore, since the dose up to 10g/kg does not cause any toxic changes in rats, it can be judged that its median lethal dose (LD50) is far greater than 10g/kg, and the compositions involved in the present invention are evaluated as safe and non-toxic substances. the

Example 3: Experiment on regulating the function of human intestinal flora

According to the Ministry of Health's "Health Food Inspection and Evaluation Technical Specifications (2003)", the evaluation method of human body test food experiment for regulating intestinal flora function, each composition prepared in Example 1 is evaluated, and the specific operation is as follows:

1. Grouping of food-testing experiments

The grouping situation of the eating experiment is shown in Table 2:

Table 2 grouping table of eating experiment

2. Human food test method

The subjects were randomly divided into 12 groups, 20 people in each group. Before the subjects tried to eat, the feces of the subjects were collected aseptically, and the intestinal flora was tested by 16SrDNA sequencing as a reference for the background level. the

According to the grouping situation in Table 2, group 1 took the control group, group 2 took the combination 1, group 3 took the combination 2, group 4 took the combination 3, group 5 took the combination 4, group 6 took the combination 5, group 7 took the combination 6, and group Group 8 took combination 7, group 9 took combination 8, group 10 took combination 9, group 11 took combination 10, and group 12 took combination 11. After 4 weeks, the feces of the subjects were collected, and the intestinal flora was tested by 16SrDNA sequencing. Compared with the bottom level, compare the multiple of its relative abundance increase. the

3. Detection method of intestinal flora

Stool samples were first extracted from DNA, and the V3-V5 region of 16SrDNA was amplified by PCR, and then sequenced on the 454 platform, and the sequencing direction was V5->V3. The raw data of each sample has an average of 7795 tags, and the read length is about 400bp. The average number of tags used for analysis is 3235, and the read length is about 265bp. the

16S analysis mainly uses mothur software (http://www.mothur.org/wiki/Mothur_manual), including quality control, OTU clustering, annotation and other analysis, and on the basis of completing the data species classification, analyze the relative abundance of each species . the

4. Experimental results

The experimental results are shown in Table 3 below:

Table 3 Comparison of the abundance of sequencing data of each genera of human intestinal flora (increased by multiple compared with the background level)

As can be seen from the data in Table 3, compared with the control group, the number of probiotics such as Eubacterium, Faecalibacterium, Roseborella, Roseburia, and Lactobacillus in the experimental group that took each composition increased significantly. increase. This shows that the composition of the present invention has a remarkable effect of regulating the intestinal flora of animals. the

Embodiment 4: hypoglycemic animal experiment

According to the animal experiment evaluation method of auxiliary hypoglycemic function of the Ministry of Health "Health Food Inspection and Evaluation Technical Specifications (2003)", each composition prepared in Example 1 is evaluated, and the specific operations are as follows:

1. Test method

Eighty male SD rats were taken, and a low-dose streptozotocin-induced diabetic rat model was prepared according to the standard method. Three days later, the rats were randomly divided into 8 groups according to the blood glucose level, with 10 rats in each group. Each group was administered intragastrically for 8 days, once a day, and the blank group was given the same amount of distilled water. Two hours after the last administration, blood was taken to measure the blood sugar level. the

2. Test object

Blank group: given distilled water;

Control group 1: Metformin was administered at a dose of 300 mg/kg;

Control group 2: give aloe vera powder, the dosage is 300mg/kg;

Control group 3: given Clostridium butyricum, the dosage was 300mg/kg

Control group 4: give propolis, the dosage is 300mg/kg

Control group 5: given aloe vera powder 0.5g aloe vera/kg/d, Clostridium butyricum 150mg/kg, in which the number of live bacteria of Clostridium butyricum was not less than 1.0×10 ⁸ CFU/g;

Experimental group 1: given combination 1 of the present invention (0.5g aloe vera/kg/d, propolis 80mg/kg, Clostridium butyricum 150mg/kg, wherein the number of live bacteria of Clostridium butyricum is not less than 1.0×10 ⁸ CFU/g) .

Experimental group 2: given combination 2 of the present invention (Lactobacillus plantarum 150mg/kg, wherein the number of viable Lactobacillus plantarum is not less than 1.0×10 ⁸ CFU/day, inulin: 1.2g/day, 0.5g aloe/kg/ d)

3. Experimental results

The results of hypoglycemia in each group are shown in Table 4. the

Table 4 Comparison of hypoglycemic effects in each group

Note: (1) *P<0.01 compared with the blank group; (2) ^Δ P<0.05 compared with the blank group

The result of table 4 shows, control 1 group, control 2 groups, control 3 groups, control 4 groups, control 5 groups and experimental group 1, experimental group 2 all have descending effect to the hyperglycemia of mice experimental diabetes, the present invention The composition and metformin have a very significant reduction effect on the hyperglycemia of mouse experimental diabetes. In combination with the experimental results in Table 2, it is shown that the composition of the present invention significantly increases the number of probiotic flora, and the increase of probiotic flora Caused the reduction of blood sugar, shows that composition of the present invention has the function of hypoglycemic, with respect to single aloe vera powder, probiotic or its combination, the effect of composition of the present invention is better in reducing the blood sugar of experimental mice, It shows that the aloe, probiotics and prebiotics in the composition of the present invention have a synergistic effect, and the present invention has obvious technical advantages and significant adjuvant therapeutic effect. the

Example 5: Hypoglycemic Human Food Trial Experiment

According to the "Technical Specifications for Inspection and Evaluation of Health Food (2003)" issued by the Ministry of Health, the human body test food experiment for lowering blood sugar was carried out. The specific operations are as follows:

1. Sample:

The samples of this test are provided by Shenzhen Huada Gene Technology Co., Ltd., and soft capsules are prepared according to Example 1 of the present invention. the

2. Human body test food and test method:

A total of 120 patients with type Ⅱ diabetes mellitus were selected on a voluntary basis, including 80 males and 40 females, aged 43-75 years, with no serious heart, liver and kidney complications. The types of therapeutic drugs, diet control and activities used by the subjects remained unchanged. According to the grouping situation in Table 2, there were 10 people in each group. Group 1 took the control group, group 2 took the combination 1, group 3 took the combination 2, and group 4 took the combination 3. Group 5 took combination 4, group 6 took combination 5, group 7 took combination 6, group 8 took combination 7, group 9 took combination 8, group 10 took combination 9, group 11 took combination 10, group 12 took combination 11, 2 times a day, 3 capsules each time, before breakfast and dinner, for 30 consecutive days. Monitor changes in the patient's blood pressure, urine, and weight, and measure fasting and 2-hour postprandial blood glucose (using the glucose oxidase method). the

3. Judging criteria:

Significant effect: the basic symptoms disappear, and the blood sugar on an empty stomach or 2 hours after a meal drops by no more than 30.0% compared with that before treatment. the

Effective: The basic symptoms are significantly improved, and the blood sugar on an empty stomach and 2 hours after a meal is less than 10.0% lower than that before treatment. the

Ineffective: The basic symptoms did not improve significantly, and the blood sugar on an empty stomach and 2 hours after meals decreased by less than 10.0% compared with before treatment. the

4. Results of human food trials

The experimental results are shown in Table 5:

Table 5 Blood glucose test results of the trial population

From the results in Table 5, it can be known that, compared with before the trial, after 30 days of trial eating the composition of the present invention, the patient's fasting blood sugar and postprandial 2h blood sugar were significantly lowered, which was significantly different than before the trial (P<0.01) . This shows that the composition of the present invention can effectively lower blood sugar by improving the intestinal flora structure, has obvious health care function of lowering blood sugar, and has no harmful effect on the health of the test population. the

In the description of this specification, descriptions referring to the terms "one embodiment", "some embodiments", "example", "specific examples", or "some examples" mean that specific features described in connection with the embodiment or example , structure, material or characteristic is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. the

Although the embodiments of the present invention have been shown and described, those skilled in the art can understand that various changes, modifications, substitutions and modifications can be made to these embodiments without departing from the principle and spirit of the present invention. The scope of the invention is defined by the claims and their equivalents. the

Claims (10)

1. A composition, characterized in that it comprises aloe, probiotics and prebiotics, wherein the mass ratio of the aloe, probiotics and prebiotics is 6:3:1 to 6:1:3. 2. The composition according to claim 1, wherein the aloe is provided in at least one form selected from aloe powder, aloe juice, aloe gel, and aloe extract, Optionally, the probiotics are selected from the group consisting of Faecalibacterium, Eubacterium, Clostridium, Fusobacterium, Rosebaria, Coprococcus, Bifidobacterium, Butyvibrio, Lactobacillus At least one species of Bacillus, Lactococcus, Optionally, the probiotics are selected from the group consisting of Eubacterium rectum, Barretella gluconovorans, Barretella enterica, Faecalibacterium prauszii, Clostridium butyricum, Bacillus coagulans, Bifidobacterium bifidus Bacillus, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium adolescentis, Lactobacillus delbrueckii bulgaricus, Lactobacillus acidophilus, Streptococcus thermophilus, Lactobacillus casei subsp. Bacillus, Bifidobacterium lactis, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus rhamnosus At least one of Lactobacillus salivarius, Propionibacterium frescheri subsp. sescheri, Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. diacetyl, and Leuconostoc enterococci subsp. , Optionally, the prebiotic is at least one selected from inulin, propolis, chitooligosaccharides, fructooligosaccharides, galactooligosaccharides, and xylooligosaccharides. 3. The use of the composition according to claim 1 or 2 in regulating animal intestinal flora. 4. The use according to claim 3, characterized in that the composition is administered to the animal at a dose of 0.5g aloe/kg/d. 5. the purposes of the composition described in claim 1 or 2 in preparing medicine, described medicine is used for regulating animal intestinal flora, Optionally, the drug is used to prevent or treat diabetes, Optionally, the composition is administered to the animal at a dose of 0.5 g aloe/kg/d. 6. A medicine, characterized in that, comprising: The composition of claim 1 or 2; and Pharmaceutically acceptable excipients. 7. The medicine according to claim 6, wherein the excipient is at least one selected from the group consisting of binders, fillers, coating polymers, plasticizers, glidants, disintegrants and lubricants A sort of, Optionally, the drug is in the form of at least one selected from capsules, pills, tablets, granules, oral liquids, internal ointments, aerosols and sprays, Optionally, the drug is used to regulate the intestinal flora of animals, Optionally, the drug is used to prevent or treat diabetes, Optionally, the drug is administered to the animal at a dose of 0.5 g aloe/kg/d. 8. A food, characterized in that, comprising: The composition of claim 1 or 2; and Food acceptable additives. 9. The medicine according to claim 6 or 7 or the food according to claim 8, used in regulating the intestinal flora of animals. 10. A method for regulating the intestinal flora of animals, characterized in that, administering the composition according to claim 1 or 2, the medicine according to claim 6 or 7 or the medicine according to claim 8 to the animal food.